Top Markets
#1 Wibx Wibx +3.22%
#2 BOT BOT +2.51%
#3 TronBank TronBank +2.45%
#4 Cysic Cysic +2.29%
#5 Starpower Starpower +2.10%
#6 Wiki Cat Wiki Cat +2.02%
#7 The Bitcoin Bull The Bitcoin Bull +1.56%
#8 Tokamak Network Tokamak Network +1.53%
#9 Audiera Audiera +1.45%
#10 SIXSEVEN SIXSEVEN +1.17%
Coin of the day
Wibx Wibx
Settings
Language
ENGLISH
Currency
USD
Theme
RBC Bioscience Corporation RBC Bioscience Corporation

RBC Bioscience Corporation

6848
Rank in Stocks #32479
RBC Bioscience Corporation is a firm dedicated to the research, development,... RBC Bioscience Corporation is a firm dedicated to the research, development, production, and sale of specialized reagents and advanced equipment. These products cater to the life sciences and molecular diagnostic sectors. Its market reach is extensive, covering Europe, the United States, Asia, Taiwan, Africa, and Australia. The company's diverse product line includes reagents tailored for molecular biomedical diagnostics and scientific research, alongside automated instruments for gene and nucleic acid extraction. It also provides a range of nucleic acid extraction kits and associated reagent tissues. Sales are primarily conducted through a global network of distributors. Established in 1995, RBC Bioscience Corporation maintains its headquarters in New Taipei City, Taiwan.
Share Price
$0.69957862
Last synced: 2026-08-17
Market Cap
$9.99M
Change (1 day)
-0.90%
Change (1 year)
18.37%
Country
TW
Trade RBC Bioscience Corporation (6848)

Category

Healthcare
Revenue for RBC Bioscience Corporation (6848)
Revenue in Aug 2026 TTM: 0
According to RBC Bioscience Corporation latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for RBC Bioscience Corporation from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE